Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
When grown as three-dimensional structures, tumor cells can acquire an additional multicellular resistance to apoptosis that may mimic the chemoresistance found in solid tumors. We developed a multicellular spheroid model of malignant mesothelioma to investigate molecular mechanisms of acquired apoptotic resistance. We found that mesothelioma cell lines, when grown as multicellular spheroids, acquired resistance to a variety of apoptotic stimuli, including combinations of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), ribotoxic stressors, histone deacetylase, and proteasome inhibitors, that were highly effective against mesothelioma cells when grown as monolayers. Inhibitors of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, particularly rapamycin, blocked much of the acquired resistance of the spheroids, suggesting a key role for mTOR. Knockdown by small interference RNA of S6K, a major downstream target of mTOR, reproduced the effect of rapamycin, thereby confirming the role of mTOR and of S6K in the acquired resistance of three dimensional spheroids. Rapamycin or S6K knockdown increased TRAIL-induced caspase-8 cleavage in spheroids, suggesting initially that mTOR inhibited apoptosis by actions at the death receptor pathway; however, isolation of the apoptotic pathways by means of Bid knockdown ablated this effect showing that mTOR actually controls a step distal to Bid, probably at the level of the mitochondria. In sum, mTOR and S6K contribute to the apoptotic resistance of mesothelioma cells in three-dimensional, not in two-dimensional, cultures. The three-dimensional model may reflect a more clinically relevant in vitro setting in which mTOR exhibits anti-apoptotic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Taking Cell-Matrix Adhesions to the Third Dimension
Cukierman, E., Pankov, R., Stevens, D. R., & Yamada, K. M. (2001) · Science · doi:10.1126/science.1064829 · Cited by 3,027
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Three-dimensional tissue culture models in cancer biology
Kim, J. B. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.05.002 · Cited by 613
mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
Dann, S. G., Selvaraj, A., & Thomas, G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.002 · Cited by 481
Cited by
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742
Multicellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
Spherical Cancer Models in Tumor Biology
Weiswald, L.-B., Bellet, D., & Dangles-Marie, V. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.004 · Cited by 1,141
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research
Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440
Advanced Cell Culture Techniques for Cancer Drug Discovery
Lovitt, C., Shelper, T., & Avery, V. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 282
Molecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
Ma, H.-L., Jiang, Q., Han, S., Wu, Y., Tomshine, J. C., Wang, D., Gan, Y., Zou, G., & Liang, X.-J. (2012) · Molecular Imaging · doi:10.2310/7290.2012.00012 · Cited by 182
Chitcholtan, K., Sykes, P. H., & Evans, J. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-38 · Cited by 148
“Some differences between spheroids and monolayers have been ascribed to PI3K/Akt/ mTOR activities [48].”
BackgroundA microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids
Ruppen, J., Cortes-Dericks, L., Marconi, E., Karoubi, G., Schmid, R. A., Peng, R., Marti, T. M., & Guenat, O. T. (2014) · Lab Chip · doi:10.1039/c3lc51093j · Cited by 105
Wen, Z., Liao, Q., Hu, Y., You, L., Zhou, L., & Zhao, Y. (2013) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20132647 · Cited by 102
Kim, H., Phung, Y., & Ho, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039556 · Cited by 68
“Broaddus and colleagues first established this method to grow mesothelioma spheroids using epithelial (M28 and REN) or sarcomatous (VAMT) lines [25].”
MethodXiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014640 · Cited by 51
“Louis, MO) was coated with 50 mL of 5 mg/mL of poly-HEMA (poly-2hydroxyethyl methacrylate; Sigma-Aldrich) in 95% ethanol and evaporated with lid on at room temperature for 72 hours [11].”
BackgroundMethodSelf-citationWang, J.-Z., Zhu, Y.-X., Ma, H.-C., Chen, S.-N., Chao, J.-Y., Ruan, W.-D., Wang, D., Du, F.-G., & Meng, Y.-Z. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.01.045 · Cited by 49
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma
Barbone, D., Van Dam, L., Follo, C., Jithesh, P. V., Zhang, S.-D., Richards, W. G., Bueno, R., Fennell, D. A., & Broaddus, V. C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150044 · Cited by 48
Self-citationZoledronic Acid Overcomes Chemoresistance and Immunosuppression of Malignant Mesothelioma
Salaroglio, I. C., Campia, I., Kopecka, J., Gazzano, E., Orecchia, S., Ghigo, D., & Riganti, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2731 · Cited by 36
“The activation of PI3K/Akt/mTOR [9, 10], osteopontin/Akt [11], macrophage colony stimulating factor-1 receptor/ Akt [12], Mcl-1/Bcl-xL [13], senescence-associated secretory phenotype/signal transducer and activator of transcription-3 (STAT3) [14] pathways, and the presence of the ATP binding cassette (ABC) transporter…”
Metadata
- Authors
- Barbone, D., Yang, T.-M., Morgan, J. R., Gaudino, G., & Broaddus, V. C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 283
- Issue
- 19
- Pages
- 13021-13030
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2086557921
- Cited by
- 150
- References
- 13
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.